XIth Eurasian Hematology-Oncology Congress - EHOC 2020

 

XIth Eurasian Hematology-Oncology Congress - EHOC 2020
Avatar

AML Highlights: Do Gilteritinib & Quizartinib Prolong OS in FLT3-Mutated R/R Disease? CPX-351 vs. CYT+DNR - What to Choose in Newly Diagnosed Disease? Are Ivo/Ena + Aza Beneficial for Chemo-Ineligible Patients?

By XIth Eurasian Hematology-Oncology Congress - EHOC 2020 FEATURING Giovanni Martinelli
By XIth Eurasian Hematology-Oncology Congress - EHOC 2020 FEATURING Giovanni Martinelli
57 views
January 11, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

18:30
Pfizer Hematology

Expert Case Review: A Treatment Option for Adult Patients With Stage…

Feat. A. Whiteley

Featured Video

07:44
Incyte

Optimizing the Management of Patients with Polycythemia Vera (PV)

Feat. P. Bose, R. Rampal
Leukemia
18:13

Pre-Pandemic CML Treatment: What Is CGA? How Do Ponatinib, Nilotinib…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

P. Raanani

15 views
19:37

Challenges in Treatment of Leukemias and Bone Marrow Failure in Deve…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

K. Rashid

15 views
23:29

AML Treatment in Developing Countries: LIMC vs. HIC Differences - St…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

E. Rego

13 views
15:57

Cytogenetic Characterization in AML: How Do Gene Mutations Impact Ov…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

M. Yilmaz

132 views
35:51

Targeted Therapy for Older Patients With AML: Is Addition of GO to I…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

C. Schiffer

38 views
18:11

State of the Art in Adults With ALL: Salvage & 1L Ino and Blina + Ch…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

E. Jabbour

23 views
14:29

How I Manage CML at MD Anderson in 2020: Are 1L Therapies Getting Be…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

E. Jabbour

33 views
17:01

Pediatric ALL Updates: What Is the COG Risk Stratification Approach?…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

S. Anak

11 views
16:00

ALL Highlights: Should We De-Escalate Chemo? Do TKIs (Dasatinib, Nil…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

D. Hoelzer

13 views
23:41

Ph+ and Ph-Like Adult Frontline ALL: What Is the Optimal Strategy in…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

R. Foa

21 views
19:05

CAR-T in Pediatric ALL: Tisagenlecleucel in B-Cell Disease, CAR-T vs…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

F. Saglio

16 views
30:27

CML Highlights: Has Molecular Monitoring Replaced Cytogenetic Monito…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

R. Hehlmann

17 views
28:52

Molecular Monitoring and CML: What Is the Influence on Therapy and H…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

N. Chaudhri

13 views
31:57

Recommendations for Treatment Discontinuation in CML: Is TFR Feasibl…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

C. Fava

13 views
11:53

CML Updates: Prognostic Factors, Conventional Drugs, 1L Therapy, Tre…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

W. Sattar

15 views
12:50

19 y/o Male With Jaundice and a Duodenal Ampulla Tumor: Does Standar…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

M. Merter

11 views
15:31

AML Updates: Can CC-486 Improve OS in 1st Remission in Older Patient…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

G. Garcia-Manero

123 views
20:42

AML Highlights: Do Gilteritinib & Quizartinib Prolong OS in FLT3-Mut…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

G. Martinelli

57 views